Saw palmetto is the most studied and the largest trials found no better than placebo. That is the finding.
Benign prostatic hyperplasia is a non-cancerous enlargement of the prostate causing lower urinary tract symptoms: frequency, nocturia, weak stream, hesitancy. It is common with age and it is important to distinguish it from prostate cancer, which is why a man with new urinary symptoms needs assessment rather than a supplement.
Saw palmetto is the important honest entry. It is the most-used herb for BPH and the most-studied. In the largest and best-designed randomised trials — including the STEP trial and the CAMUS trial, both of which used higher doses and longer follow-up than the earlier positive studies — saw palmetto was not better than placebo for urinary symptoms. The earlier positive trials were smaller and shorter. This is the classic pattern of a herb whose effect dissolved under better testing, and a handbook that reported only the earlier trials would be misleading.
Nettle root has small trials showing modest symptom improvement, often in combination. Pygeum africanum has small trials and a signal, of low quality. Beta-sitosterol (a plant sterol) has small trials showing improvement.
What actually works. For mild symptoms: reducing evening fluid intake, reducing caffeine and alcohol, and treating constipation. Alpha-blockers (tamsulosin and others) work quickly and are effective. 5-alpha-reductase inhibitors (finasteride) shrink the prostate and reduce the risk of retention and surgery, with sexual side effects. Combination therapy. Surgery for severe or refractory cases. And an assessment to exclude prostate cancer and to check kidney function — a man with a rising creatinine from obstruction needs treatment, not a supplement.
The overactive bladder point. Frequent urination can be BPH, or overactive bladder, or diabetes, or a diuretic, or a urinary infection. The distinction matters because the treatments differ and because the causes that need looking for are not prostate supplements.
Meta-Analysis2025Age and ageing
The importance of electrical parameters on transcutaneous tibial nerve stimulation for overactive bladder syndrome: a systematic review and meta-analysis.
Electrical parameters may impact effectiveness (in favour of 10 Hz, motor threshold).
PubMed 40711757 ↗
Meta-Analysis2024Brazilian journal of physical therapy
Isolated bladder training or in combination with other therapies to improve overactive bladder symptoms: a systematic review and meta-analysis of randomized controlled trials.
In the short term, BT plus IVES improves the OAB symptoms of nocturia and UI while improving QoL.
PubMed 39106788 ↗
Meta-Analysis2023International braz j urol : official journal of the Brazilian Society of Urology
Comparative assessment of efficacy and safety of approved oral therapies for overactive bladder: a systematic review and network meta-analysis.
For safety, most anticholinergic drugs were more likely to cause dry mouth and constipation, lower doses were better tolerated.
PubMed 37506033 ↗
Meta-Analysis2012Neurourology and urodynamics
Effectiveness of percutaneous posterior tibial nerve stimulation for overactive bladder: a systematic review and meta-analysis.
There is evidence of significant improvement in OAB symptoms using PTNS which is comparable to the effect of antimuscarinics but with a better side effect profile.
PubMed 22581511 ↗
Meta-Analysis2009Journal of ethnobiology and ethnomedicine
American palm ethnomedicine: a meta-analysis.
Some, like Serenoa repens and Roystonea regia, are the sources of drugs that have been approved for medicinal uses.
PubMed 20034398 ↗
Meta-Analysis2000Public health nutrition
Phytotherapy for benign prostatic hyperplasia.
Randomized studies of Serenoa repens, alone or in combination with other plant extracts, have provided the strongest evidence for efficacy and tolerability in treatment of BPH in comparison with other phytotherapies.
PubMed 11276294 ↗